Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Nursing | Pediatrics | Pharmacy | Emergency Medicine | Journal

Back to Journal Articles

Single Topical Ivermectin Head Lice Treatment Very Effective

Last Updated: October 31, 2012.

 

Ten-minute, at-home ivermectin treatment eliminates lice in nearly all patients by the next day

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

WEDNESDAY, Oct. 31 (HealthDay News) -- A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

David M. Pariser, M.D., from the Eastern Virginia Medical School in Norfolk, and colleagues randomly assigned 765 patients with head lice (6 months of age or older) to a single application of 0.5 percent ivermectin lotion or vehicle control without nit combing.

The researchers found that a significantly greater percentage of the ivermectin group was free of lice on day two (94.9 versus 31.3 percent), day eight (85.2 versus 20.8 percent), and day 15 (73.8 versus 17.6 percent). Both groups had similar frequency and severity of adverse events.

"In conclusion, ivermectin has a well-established safety profile, on the basis of extensive oral use, and a novel mode of action," Pariser and colleagues conclude. "Topical ivermectin showed high efficacy within 24 hours, with most treated patients remaining louse-free through the final assessment two weeks after a single treatment, without the need for nit combing."

The study was funded by Topaz Pharmaceuticals (now Sanofi Pasteur), which provided the study medication; two authors disclosed financial ties to Topaz Pharmaceuticals and Sanofi Pasteur.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Sustained Release Naltrexone Effective, Safe for Opioid Users Next: Once-Yearly Zoledronic Acid Benefits Men With Osteoporosis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.